CareDx (CDNA) Scheduled to Post Quarterly Earnings on Monday

CareDx (NASDAQ:CDNA - Get Free Report) is set to announce its earnings results after the market closes on Monday, November 4th. CareDx has set its FY 2024 guidance at EPS.Persons that wish to listen to the company's earnings conference call can do so using this link.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.37. The firm had revenue of $92.27 million during the quarter, compared to analysts' expectations of $67.20 million. CareDx had a negative return on equity of 53.65% and a negative net margin of 53.73%. On average, analysts expect CareDx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CareDx Stock Up 2.2 %

CDNA traded up $0.50 on Monday, reaching $22.89. The company's stock had a trading volume of 608,818 shares, compared to its average volume of 902,837. CareDx has a fifty-two week low of $4.92 and a fifty-two week high of $34.84. The stock has a 50 day moving average of $29.04 and a two-hundred day moving average of $20.25. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -6.72 and a beta of 1.77.

Insider Buying and Selling at CareDx

In other news, Director Peter Maag sold 35,552 shares of the company's stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $33.04, for a total transaction of $1,174,638.08. Following the transaction, the director now directly owns 330,024 shares of the company's stock, valued at $10,903,992.96. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Alexander L. Johnson sold 34,231 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $33.55, for a total value of $1,148,450.05. Following the sale, the insider now directly owns 284,983 shares of the company's stock, valued at approximately $9,561,179.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Peter Maag sold 35,552 shares of CareDx stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $33.04, for a total transaction of $1,174,638.08. Following the transaction, the director now owns 330,024 shares of the company's stock, valued at approximately $10,903,992.96. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 91,340 shares of company stock valued at $3,025,415. 4.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

CDNA has been the subject of several research analyst reports. Craig Hallum upped their price objective on shares of CareDx from $22.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, August 1st. The Goldman Sachs Group raised their price target on CareDx from $26.00 to $35.00 and gave the stock a "buy" rating in a research note on Wednesday, October 16th. Wells Fargo & Company initiated coverage on CareDx in a report on Tuesday, August 27th. They issued an "underweight" rating and a $28.00 price objective for the company. StockNews.com upgraded shares of CareDx from a "hold" rating to a "buy" rating in a research report on Thursday, October 17th. Finally, HC Wainwright reiterated a "neutral" rating on shares of CareDx in a research report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, CareDx presently has an average rating of "Moderate Buy" and an average price target of $30.60.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.